Skip to main content
Figure 3 | Journal of Hematology & Oncology

Figure 3

From: G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responses

Figure 3

CD8+T cell responses are normal in the context of G-CSF/anti-G-CSF mAb-mediated expansion of CD11b+Gr-1+myeloid cells. (A) OT-I CD8+ T cells (105) were transferred to B6 mice and infected with VSV-OVA one day later. On day 1, day 2, and day 3 post-infection, mice were treated i.p. with G-CSF/anti-G-CSF mAb complexes (1 μg G-CSF plus 5 μg anti-G-CSF mAb), G-CSF alone (1 μg G-CSF), or vehicle alone (n = 4/group). (B) Peripheral blood was harvested at the timepoints indicated and the percentage of donor OT-I CD8+ T cells among lymphocytes was assessed. (C) As in 'B’ except the percentage of myeloid cells (CD11b+Gr-1+) among peripheral blood cells was assessed. (D) Representative data from 'C’ on day 4. (E) OT-I CD8+ T cells (106) were transferred to B6 mice on day -1. On day 0, day 1, and day 2, mice were injected i.p. with G-CSF/anti-G-CSF complexes (1.5 μg G-CSF plus 7.5 μg anti-G-CSF mAb). On day 1, mice also received 50 μg of OVA peptide i.v. followed shortly afterwards with one injection i.p. of poly I:C (n = 2-3/group). (F) Peripheral blood was harvested at the time-points indicated and the percentage of donor OT-I CD8+ T cells among lymphocytes was assessed. (G) As in 'F’ except the percentage of myeloid cells (CD11b+Gr-1+) among peripheral blood cells was assessed. (H) Representative data from 'G’ on day 3. The error bars in 'B’, 'C’, 'F’, and 'G’, indicate standard deviation.

Back to article page